Drug name - Dexilant Solutab
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(4 months from now) | |
| CN1150186C | TAKEDA PHARMS USA | Benzimidazole Compound Crystal |
Jun, 2020
(2 years ago) | |
| CN1355798A | TAKEDA PHARMS USA | Benzimidazole Compound Crystal |
Jun, 2020
(2 years ago) | |
| EP1977751A1 | TAKEDA PHARMS USA | Amorphous (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole As Anti-Ulcer Agent |
Jun, 2020
(2 years ago) | |
| EP1977751B1 | TAKEDA PHARMS USA | Amorphous (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole As Anti-Ulcer Agent |
Jun, 2020
(2 years ago) | |
| EP1129088A2 | TAKEDA PHARMS USA | Crystalline Form Of (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole |
Jun, 2020
(2 years ago) | |
| EP1129088B1 | TAKEDA PHARMS USA | Crystalline Form Of (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole |
Jun, 2020
(2 years ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6664276
(Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(9 months from now) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(1 year, 15 days from now) | |
|
US8784885
(Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(1 year, 6 months from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(3 years from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(3 years from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(3 years from now) | |
|
US8461187
(Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(3 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(5 years from now) | |
|
US8871273
(Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(5 years from now) | |
| US9241910 | TAKEDA PHARMS USA | Orally-disintegrating solid preparation |
Mar, 2029
(6 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 30MG | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.